Modest growth rate forecast for hemophilia A and B market

The combined market value for hemophilia A and B across the seven major countries of the USA, France, Germany, Italy, Spain, the UK and Japan is set to rise from $6.7 billion in 2016 to almost $8.0 billion in 2026, representing a compound annual growth rate (CAGR) of 1.8%.

According to research and consulting firm GlobalData’s latest report, the drivers of this modest growth include increasing rates of routine prophylaxis in pediatric and adult hemophilia A and B, and the introduction and uptake of new long-acting factors and alternative coagulation promoters (ACPs).

Chiara Marchetti, healthcare analyst for GlobalData, explains: “The hemophilia A market has historically been crowded with several comparable short-acting recombinant factor VIII (rFVIII) treatment options. Developers had hoped that the launches of long-acting rFVIII products since 2014 would stimulate this stagnant segment, but the transition to these drugs has been slower than expected.”